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小児心臓移植後の移植後リンパ増殖性疾患（PTLD）
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Post-transplant lymphoproliferative disorders (PTLD) remain a significant cause of morbidity and mortality
after pediatric heart transplantation. More than 80 % of cases are of B-cell origin and are positive for Epstein-Barr
virus (EBV). The pathogenesis of EBV-positive PTLD appears to be correlated with the uncontrolled proliferation
of latently EBV-infected B cells arising from a lack of EBV-specific cytotoxic T-lymphocyte function. PTLD in-
cludes a spectrum of diseases ranging from reactive lymphoid proliferation to malignant lymphoma. The risk fac-
tors underlying the development of PTLD include the degree of immunosuppression, the EBV serostatus of the
recipient, the time since transplantation, and the recipient’s age and ethnicity. In the pediatric age group, most
PTLD cases occur in EBV-negative recipients of EBV-positive donor organs. As part of routine evaluations of pa-
tients with a high risk of PTLD, EBV monitoring is useful for the early detection of this complication. A high in-
dex of suspicion is key to an early and accurate diagnosis of PTLD. The subsequent therapeutic goals are the
eradication of PTLD and the preservation of graft function. The treatment outcomes for PTLD have steadily im-
proved over the past decade, partly because of the availability of rituximab and everolimus.












最も多く 20 %以上を占める２）．小児心臓移植後 10
年における悪性新生物の発症率は 9.3 %，その内 95
％以上をリンパ腫が占め３），移植後リンパ増殖性疾患
（post-transplant lymphoproliferative disorders ：
PTLD）は，心臓移植患者のmortality と morbidity
に関与する重大な合併症であり，臓器移植後の管理
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Table　1　Correlations between EBV-positive PTLD and specific EBV latency programs
Latency Type I Type II Type III
Type of PTLD Burkitt lymphoma Hodgkin lymphoma PTCL DLBCL
Expressed EBV gene products
　EBER ＋ ＋ ＋
　EBNA1 ＋ ＋ ＋
　EBNA2, 3 － － ＋
　LMP1 － ＋/－ ＋
　LMP2A, 2B － ＋/－ ＋
EBV, Epstein-Barr virus; PTLD, post-transplant lymphoproliferative disorders; PTCL, peripheral T-
cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EBER, Epstein-Barr virus-encoded RNA; 





































































Table　2　Incidences of PTLD according to trans-
planted organ
Transplanted organ Pediatric PTLD Adult PTLD
Heart -6 % 1.0-6.3 %
Kidney 2-3 % 1.0-2.3 %
Liver 5-10 % 1.0-2.3 %
Lung -15 %  2.4-10.0 %




















































































Table　3　Categories of post-transplant lymphoprolif-






  (classified according to the type of lymphoma that they 
resemble)
　B-cell neoplasms






　　Peripheral T-cell lymphoma, NOS (PTCL-NOS)
　　Hepatosplenic T-cell lymphoma
　Other
IV Classical Hodgkin lymphoma-type PTLD
Table　4　Summary of pathologic and clinical features of PTLD







Early lesion Polyclonal/ 
Oligoclonal
Absent ＋ None High
Polymorphic Oligoclonal/ 
Monoclonal
Present ＋ BCL6 Varies
Monomorphic ＋







HL Varies Present ＋ Not known Poor
DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PTCL-NOS, Peripheral T-cell 










phic PTLD，Monomorphic PTLDからなるが，前 2
者は B細胞性であり，T/NK細胞性のほとんどは







































Table　5　Diagnostic workup for suspected PTLD
Routine Selected
CBC, differential Gastrointestinal endoscopy
Serum Na, K, Cl, Ca, BUN, Creat, UA Bone scan
Alb, AST, ALT Bone marrow biopsy
LDH, ferritin, sIL2R Lumber puncture
Immunoglobulins IgG, IgA, IgM PET
EBV serologies EBV　VCA-IgG, EADR-IgG, 
EBNA
Brain CT/MRI
EBV viral load from peripheral whole blood
Stools Occult bleeding
Chest radiograph
CT scan of neck/chest/abdomen/pelvis
Biopsy Routine morphology Chromosome/Genetic studies


































































Fig.　1　Macroscopic findings for resected lesion (case 2)
The resected ileum shows the development of an 
ulcer (maximum diameter, 6.0 cm) and lymph node 
enlargement (diameters, 1.5-2.0 cm).
Table　6　Characteristics of Five Pediatric PTLD Cases
Case 1 Case 2 Case 3 Case 4 Case 5
Gender male male male male male
Underlying Disease DCM DCM DCM DCM RCM
Age at HTx 5 years 3 years 1 years 7 months 9 years
Age at PTLD Dx 11 years 10 years 4 years 4 years 14 years
Immunosuppression TAC, MMF, 
　Prior to PTLD TAC, PSL TAC PSL TAC, MMF TAC, MMF
EBV status
　IgG at Transplantation Negative Negative Negative Negative Negative
　IgG of Donor N/A Positive N/A Positive N/A










LDH (U/L)   378   299   252 1,471 202









Treatment Rituximab Capizzi Rituximab FAB/LMB96 FAB/LMB96
Outcome Remission Remission Remission Remission Remission
Follow-up Period (years) 11 10 6 3 1
DCM, dilated cardiomyopathy; RCM, restrictive cardiomyopathy; Dx, diagnosis; TAC, tacrolimus; MMF, mycophenolate 
mofetil; PSL, Prednisolone; EBV, Epstein-Barr virus; N/A, not available; PB, peripheral blood; ND, not detected; PTCL-
NOS, peripheral T-cell lymphoma-not otherwise specified.
Table　7　EBV serological findings of Five Pediatric PTLD Cases
Case 1 Case 2 Case 3 Case 4 Case 5
VCA-IgG (FA) 320× 1,280× 2,560× ＜10× 160×
EA-IgG (FA) 80× 320× 80× ＜10× ＜10×
EBNA ＜10×(FA) ＜10×(FA) ＜10×(FA) ＜10×(FA) 1.1 (EIA)
EBV-DNA in PB (RT-PCR) 
(copies/106cells) 
1.6×103 8.5×102 2.2×105 ND 1.5×103
EBV, Epstein-Barr virus; VCA, viral capsid antigen; EA, early antigen; EBNA, Epstein-Barr nuclear antigens; 




















Fig.　2　Abdominal CT findings (case 4)
A bulky mass (maximum diameter, 20.0 cm) arising 
from the terminal ileum is visible.
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